<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55845</article-id><article-id pub-id-type="doi">10.7554/eLife.55845</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Identification of a novel toxicophore in anti-cancer chemotherapeutics that targets mitochondrial respiratory complex I</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-175416"><name><surname>Stephenson</surname><given-names>Zoe A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175417"><name><surname>Harvey</surname><given-names>Robert F</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175418"><name><surname>Pryde</surname><given-names>Kenneth R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175420"><name><surname>Mistry</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175422"><name><surname>Hardy</surname><given-names>Rachel E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175423"><name><surname>Serreli</surname><given-names>Riccardo</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175426"><name><surname>Chung</surname><given-names>Injae</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2902-4677</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175427"><name><surname>Allen</surname><given-names>Timothy EH</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175428"><name><surname>Stoneley</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175430"><name><surname>MacFarlane</surname><given-names>Marion</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-81734"><name><surname>Fischer</surname><given-names>Peter M</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-9886"><name><surname>Hirst</surname><given-names>Judy</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-175429"><name><surname>Kellam</surname><given-names>Barrie</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0030-9908</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-174495"><name><surname>Willis</surname><given-names>Anne E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1470-8531</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">MRC Toxicology Unit</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Leicester</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">School of Pharmacy, Biodiscovery Institute</institution>, <institution>University of Nottingham</institution>, <addr-line><named-content content-type="city">Nottingham</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">MRC Mitochondrial Biology Unit</institution>, <institution>University of Cambridge</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><institution content-type="dept">Division of Biomolecular Science and Medicinal Chemistry, School of Pharmacy</institution>, <institution>University of Nottingham</institution>, <addr-line><named-content content-type="city">Nottingham</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution content-type="dept">Mitochondrial Biology Unit</institution>, <institution>Medical Research Council</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-10241"><name><surname>Topisirovic</surname><given-names>Ivan</given-names></name><role>Reviewing editor</role><aff><institution>Jewish General Hospital</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>jh@mrc-mbu.cam.ac.uk</email> (JH);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>barrie.kellam@nottingham.ac.uk</email> (BK);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>aew80@cam.ac.uk</email> (AW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>05</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e55845</elocation-id><history><date date-type="received"><day>07</day><month>02</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>05</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Stephenson et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Stephenson et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55845-v1.pdf"/><abstract><p>Disruption of mitochondrial function selectively targets tumour cells that are dependent on oxidative phosphorylation. However, due to their high energy demands, cardiac cells are disproportionately targeted by mitochondrial toxins resulting in a loss of cardiac function. An analysis of the effects of mubritinib on cardiac cells showed that this drug did not inhibit HER2 as reported, but directly inhibits mitochondrial respiratory complex I, reducing cardiac-cell beat rate, with prolonged exposure resulting in cell death. We used a library of chemical variants of mubritinib and showed that modifying the 1H-1,2,3-triazole altered complex I inhibition, identifying the heterocyclic 1,3-nitrogen motif as the toxicophore. The same toxicophore is present in a second anti-cancer therapeutic carboxyamidotriazole (CAI) and we demonstrate that CAI also functions through complex I inhibition, mediated by the toxicophore. Complex I inhibition is directly linked to anti-cancer cell activity, with toxicophore modification ablating the desired effects of these compounds on cancer cell proliferation and apoptosis.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MC_UU_000 /RG94521</award-id><principal-award-recipient><name><surname>Stephenson</surname><given-names>Zoe A</given-names></name><name><surname>Harvey</surname><given-names>Robert F</given-names></name><name><surname>Pryde</surname><given-names>Kenneth</given-names></name><name><surname>Willis</surname><given-names>Anne E</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MC_U105663141 and MC_UU_00015/2</award-id><principal-award-recipient><name><surname>Hirst</surname><given-names>Judy</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files</p></sec><supplementary-material><ext-link xlink:href="elife-55845-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>